VXRT
Vaxart, Inc.Company Information
- Company Name
- Vaxart, Inc.
- CIK
- CIK0000072444
- Category
- Accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- VXRT: OTC
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- VXRT
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-05-22
- Last sale
- —
- Shares purchased (TTM)
- 180,000
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 39,702
- Shares outstanding
- 242,165,410
- Ownership
- 0.02%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- -12.28%
- 3-month reaction
- Pending
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 51 | 51 | 54 | 17 | 20 | 29 | 25 | 22 | 43 | 27 | 35 | 33 | ||||||
| Short Term Investments | 13 | 10 | 10 | 12 | 6 | 13 | 26 | 37 | 19 | 10 | 5 | 20 | ||||||
| Accounts Receivable Net Current | 0 | 7 | 15 | 43 | 4 | 2 | 6 | 1 | 1 | 1 | 3 | 0 | ||||||
| Unbilled Receivables Current | 47 | 50 | 37 | 43 | 37 | 15 | 6 | 3 | 4 | - | 0 | - | ||||||
| Prepaid Expense And Other Assets Current | 6 | 13 | 21 | 3 | 3 | 5 | 5 | 4 | 4 | 7 | 3 | 4 | ||||||
| Assets Current | 117 | 132 | 136 | 117 | 70 | 63 | 68 | 66 | 72 | 44 | 46 | 57 | ||||||
| Property Plant And Equipment Net | 6 | 5 | 5 | 6 | 7 | 8 | 9 | 9 | 10 | 11 | 12 | 13 | ||||||
| Prepaid Expense Other Noncurrent | 25 | 25 | 25 | 60 | 60 | 60 | 60 | 60 | - | - | 0 | - | ||||||
| Operating Lease Right Of Use Asset | 10 | 11 | 11 | 17 | 18 | 19 | 20 | 22 | 23 | 24 | 25 | 26 | ||||||
| Intangible Assets Net Excluding Goodwill | 2 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | ||||||
| Goodwill | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Other Assets Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Assets | 165 | 180 | 186 | 209 | 164 | 159 | 166 | 167 | 114 | 89 | 92 | 106 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 17 | 24 | 21 | 53 | 11 | 17 | 7 | 3 | 4 | 4 | 2 | 1 | ||||||
| Deferred Revenue Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Accrued Liabilities Current | 43 | 37 | 48 | 45 | 36 | 10 | 11 | 7 | 7 | 5 | 6 | 6 | ||||||
| Operating Lease Liability Current | 3 | 3 | 3 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | ||||||
| Liabilities Current | 73 | 77 | 87 | 169 | 118 | 99 | 91 | 80 | 16 | 14 | 14 | 11 | ||||||
| Operating Lease Liability Noncurrent | 5 | 5 | 6 | 12 | 13 | 14 | 14 | 15 | 16 | 17 | 17 | 18 | ||||||
| Deferred Revenue Noncurrent | 2 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Other Liabilities Noncurrent | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities | 83 | 86 | 98 | 182 | 131 | 113 | 107 | 98 | 34 | 33 | 34 | 34 | ||||||
Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 551 | 550 | 548 | 542 | 540 | 538 | 536 | 534 | 531 | 490 | 468 | 464 | ||||||
| Treasury Stock Common Value | -0 | -0 | -0 | -0 | -0 | -1 | -0 | -1 | -1 | -1 | -0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -469 | -455 | -460 | -515 | -507 | -492 | -477 | -465 | -450 | -434 | -410 | -392 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | -0 | -0 | -0 | -0 | 0 | 0 | -0 | -0 | -0 | -0 | ||||||
| Stockholders Equity | 82 | 94 | 88 | 27 | 33 | 46 | 59 | 68 | 80 | 56 | 58 | 72 | ||||||
| Liabilities And Stockholders Equity | 165 | 180 | 186 | 209 | 164 | 159 | 166 | 167 | 114 | 89 | 92 | 106 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 350 | 350 | 250 | 350 | 350 | 350 | 350 | 350 | 350 | 250 | 250 | 250 | ||||||
| Common Stock Shares Issued | 243 | 242 | 241 | 229 | 229 | 229 | 228 | 228 | 228 | 177 | 154 | 152 | ||||||
| Shares Outstanding | 243 | 241 | 240 | 229 | 229 | 228 | 228 | 227 | 227 | 177 | 153 | 152 | ||||||
| Treasury Stock Common Shares | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialVaxart, Inc. (VXRT) — SEC Financial Statements & Analysis
Vaxart, Inc. (VXRT) is a biological products, (no diagnostic substances) company, incorporated in DE. Vaxart, Inc. trades on OTC as: VXRT. Vaxart, Inc. (VXRT)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Vaxart, Inc. carries a market cap of $147.72M, a P/E ratio of 3.83x, a P/B ratio of 1.79x, a P/S ratio of 0.61x, an enterprise value of $96.79M, and an EV/EBITDA multiple of 2.12x. On profitability, it posts an operating margin of 16.30%, a net margin of 15.88%, a Return on Equity (ROE) of 66.97%, a Return on Assets (ROA) of 23.44%, and a Return on Invested Capital (ROIC) of 154.63%. Per share, it reports EPS of $0.16, diluted EPS of $0.15, free cash flow per share of $0.14, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 201.10% year-over-year, net income growth of -168.13% year-over-year, and EPS growth of -164.25% year-over-year. On the balance sheet, it maintains a current ratio of 1.60x, a quick ratio of 1.52x, working capital of $43.58M, a debt-to-equity ratio of 1.01x, a debt ratio of 0.5, an interest coverage ratio of 20.03x, free cash flow of $33.38M (TTM), and net debt of $-50.93M. Figures sourced from SEC EDGAR.
- Market Cap
- $147.72M
- P/E TTM
- 3.83x
- EPS TTM
- $0.16
- P/B TTM
- 1.79x
- ROE TTM
- 66.97%
- ROA TTM
- 23.44%
- Debt To Equity
- 1.01x
- Free Cash Flow TTM
- $33.38M
- Net Revenue TTM Growth 1Y
- 201.10%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Vaxart, Inc. in?
Vaxart, Inc. (VXRT) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does VXRT trade on?
Vaxart, Inc. (VXRT) trades on the OTC.
Where is Vaxart, Inc. incorporated?
Vaxart, Inc. is incorporated in DE.
When was Vaxart, Inc. (VXRT)'s most recent SEC filing?
Vaxart, Inc. (VXRT)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is VXRT's market cap?
Vaxart, Inc. (VXRT) has a market capitalization of $147.72M as of 2026-06-30.
What is VXRT's P/E ratio?
Vaxart, Inc. (VXRT)'s trailing twelve month P/E ratio is 3.83x as of 2026-06-30.
What is VXRT's EPS (earnings per share)?
Vaxart, Inc. (VXRT)'s trailing twelve month EPS is $0.16 as of 2026-06-30.
What is VXRT's ROE (return on equity)?
Vaxart, Inc. (VXRT)'s trailing twelve month Return on Equity (ROE) is 66.97% as of 2026-06-30.
What is VXRT's ROA (return on assets)?
Vaxart, Inc. (VXRT)'s trailing twelve month Return on Assets (ROA) is 23.44% as of 2026-06-30.
What is VXRT's ROIC (return on invested capital)?
Vaxart, Inc. (VXRT)'s trailing twelve month Return on Invested Capital (ROIC) is 154.63% as of 2026-06-30.
What is VXRT's EV/EBITDA?
Vaxart, Inc. (VXRT)'s trailing twelve month EV/EBITDA is 2.12x as of 2026-06-30.